



## Alzinova participates in several conferences and investor meetings in the spring of 2024

Alzinova AB (publ) (ticker: ALZ) plans to both present and attend several partner conferences and investor meetings during the spring of 2024. In June, Alzinova will attend the Biotech International Convention, ("US Bio") which is an important US business conference for partner meetings. Alzinova will also present its favourable results at various capital markets days.

Alzinova's strategy to develop a safe and effective treatment for Alzheimer's disease has attracted increasing interest from both the pharmaceutical community and investors. The promising results from the phase 1b study with the vaccine candidate ALZ-101 show that the study achieved both primary and secondary endpoints. In addition, further analysis of the data from the study shows a positive change in biomarkers associated with Alzheimer's disease.

With this positive progress, the company has stepped up its presence at various conferences to expand its contacts with potential investors and big pharmaceutical companies. The goal is to establish global partnerships to further develop the vaccine candidate and accelerate the process of bringing it to market. During the spring, Alzinova will participate in a number of partnering and investor events.

### **Biotech International Convention - US BIO, June 3 – 6**

BIO International Convention is the world's largest meeting place for pharmaceutical and biotechnology companies. The event attracts over 14,000 biotechnology and pharmaceutical industry leaders to a week of intensive networking to discover new opportunities, enable collaboration and partnering discussions, and investor meetings. In total, over 3,000 companies from over 30 countries are participating. Alzinova's Business Development Director, Sebastian Hansson, will meet potential partners and present the strong data obtained from the phase 1b study. Read more here: <https://www.bio.org/events/bio-international-convention>

### **Redeye Investor Forum, May 16**

CEO Kristina Torfgård will present at Redeye Investor Forum which is a live broadcast where different companies will hold a 12-minute presentation followed by an 8-minute Q&A session moderated by Redeye analysts. You can ask your question directly to Alzinova during the live broadcast in the questionnaire available on Redeye's website: <https://www.redeye.se/events/1973447/investor-forum-online-28>

### **Carnegie Digital Health Day, Week 23**

At the Carnegie Digital Health Day, Alzinova's CEO Kristina Torfgård will present the company and the latest developments. The recording will be available on Alzinova's website during week 23.



**Aktiespararna Aktiedagarna, June 11**

Kristina Torfgård will present the company at Aktiespararna's event "Aktiedagarna" in Stockholm on June 11. The event is held with both physical participation and through live broadcast where the presentation and Q&A session lasts for about 25 minutes starting at 08.25. For more information about the event: <https://www.aktiespararna.se/aktiviteter/aktiedagarna-42149>

**For more information, please contact:**

Kristina Torfgård, CEO  
Tel. +46 708 46 79 75  
E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*

**About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

**Attachments**

**Alzinova participates in several conferences and investor meetings in the spring of 2024**